Novartis AG

Novartis unveils Phase‑III success for Fabhalta and Vanrafia, showing significant proteinuria and BP reductions while preserving kidney function—boosting investor confidence and reshaping nephrology treatment.

Novartis’s 24% operating‑income jump, ianalumab Phase III success and Tourmaline Bio acquisition signal a strategic shift toward rare‑disease innovation and CRISPR‑based therapies. Discover the upside, risks and analyst views shaping its future.

Novartis has secured US regulatory approval for Rhapsido, its first oral Bruton’s tyrosine kinase inhibitor for chronic spontaneous urticaria, positioning the company to capture a growing market segment and potentially generate significant revenue.

Novartis has formed a partnership with BioArctic to develop a new treatment for neurodegenerative diseases, leveraging BioArctic’s cutting-edge technology and Novartis’ pharmaceutical expertise.

Novartis’ stock price has seen a moderate increase due to a positive market sentiment driven by investor confidence in the company’s future prospects and commitment to innovation.

Novartis AG has made significant progress in research and development, with a Phase III study for its treatment candidate ianalumab showing promising results in treating primary immune thrombocytopenia (ITP).

Novartis AG’s breakthrough drug candidate, Ianalumab, has exceeded expectations in clinical trials for ITP and Sjögren’s disease, leading to a significant increase in stock price and solidifying the company’s position as a leader in medical researc…

Novartis’ stock price sees a modest increase amid rumors of potential takeover talks with US biotech firm Avidity Biosciences.

Novartis is facing a significant challenge from US trade policies, but sees an opportunity to capitalize on the growing interstitial cystitis market.

Novartis receives FDA approval for its medication Leqvio, but its stock price is impacted by US President Trump’s demands for lower medication prices.